Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rowin, J.
Right arrow Articles by Meriggioli, M. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rowin, J.
Right arrow Articles by Meriggioli, M. N.
Related Collections
Right arrow Muscle disease
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrowRelated Article
NEUROLOGY 2006;66:1245-1247
© 2006 American Academy of Neurology
Brief Communications

Mycophenolate mofetil in dermatomyositis: Is it safe?

J. Rowin, MD, A. A. Amato, MD, N. Deisher, MD, J. Cursio and M. N. Meriggioli, MD

From the Section of Neuromuscular Disease (J.R., M.N.M.), Department of Neurology and Rehabilitation, University of Illinois at Chicago, IL; Neuromuscular Division (A.A.A.), Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Neurological Sciences (N.D.), Rush University, Chicago, IL; and Center for Stroke Research (J.C.), University of Illinois at Chicago, IL.

Address correspondence and reprint requests to Dr. Julie Rowin, EMG Laboratory, Department of Neurology and Rehabilitation, University of Illinois at Chicago, Neuropsychiatric Institute (MC 796), 912 South Wood Street, Room 855N, Chicago, IL 60612-7330; e-mail: rowin{at}uic.edu

The authors report 10 patients with idiopathic dermatomyositis treated with mycophenolate mofetil in combination with corticosteroids. Successful steroid taper without disease relapse was achieved in six patients; however, in three patients, treatment was associated with opportunistic infections, leading to death in one patient. The disproportionately high rate of opportunistic infections in this group is considered.

Disclosure: Dr. Meriggioli has received speaker's honoraria from Aspreva Pharmaceuticals.

Received October 11, 2005. Accepted in final form January 4, 2006.


Related Article

April 25 Highlights
Neurology 2006 66: 1136-1137. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A A Amato and R J Barohn
Evaluation and treatment of inflammatory myopathies
J. Neurol. Neurosurg. Psychiatry, October 1, 2009; 80(10): 1060 - 1068.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
P F Finelli, K Naik, J A DiGiuseppe, and A Prasad
Primary lymphoma of CNS, mycophenolate mofetil and lupus
Lupus, December 1, 2006; 15(12): 886 - 888.
[Abstract] [PDF]

Home page
 Journal Watch DermatologyHome page
The Safety of Mycophenolate Mofetil for Dermatomyositis
Journal Watch Dermatology, June 13, 2006; 2006(613): 3 - 3.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.